4//SEC Filing
Patel Samir Rashmikant 4
Accession 0000950170-24-128190
CIK 0001541157other
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 8:02 PM ET
Size
6.7 KB
Accession
0000950170-24-128190
Insider Transaction Report
Form 4
Patel Samir Rashmikant
Director
Transactions
- Award
Ordinary Shares, par value $0.0001 per share
2024-11-14+1,404,622,000→ 4,816,117,500 total(indirect: By LLC)
Holdings
- 91,396,000
Ordinary Shares, par value $0.0001 per share
Footnotes (3)
- [F1]The Ordinary Shares may be represented by American Depositary Shares ("ADSs"), each of which currently represents 2,000 Ordinary Shares.
- [F2]This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. ("Peak Bio"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Issuer ("Merger Sub"), pursuant to which Merger Sub merged with and into Peak Bio effective as of November 14, 2024, with Peak Bio surviving as a wholly owned subsidiary of the Issuer (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Peak Bio (each, a "Peak Share") was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") ADSs.
- [F3]Represents the number of Ordinary Shares acquired by the Reporting Person from the exchange of Peak Shares held by the Reporting Person at the Effective Time in accordance with the Exchange Ratio.
Documents
Issuer
Akari Therapeutics Plc
CIK 0001541157
Entity typeother
Related Parties
1- filerCIK 0001702447
Filing Metadata
- Form type
- 4
- Filed
- Nov 17, 7:00 PM ET
- Accepted
- Nov 18, 8:02 PM ET
- Size
- 6.7 KB